Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2013 | 11.04 Million USD | -60.11% |
| 2012 | 27.68 Million USD | -10.03% |
| 2011 | 30.77 Million USD | -35.55% |
| 2010 | 47.74 Million USD | -1.15% |
| 2009 | 48.3 Million USD | 18.21% |
| 2008 | 40.85 Million USD | 45.73% |
| 2007 | 28.03 Million USD | 48.03% |
| 2006 | 18.94 Million USD | 621.78% |
| 2005 | 2.62 Million USD | 32.82% |
| 2004 | 1.97 Million USD | -62.84% |
| 2003 | 5.31 Million USD | -6.8% |
| 2002 | 5.7 Million USD | 216.32% |
| 2001 | 1.8 Million USD | 8.57% |
| 2000 | 1.66 Million USD | -74.04% |
| 1999 | 6.4 Million USD | 255.56% |
| 1998 | 1.8 Million USD | -10.0% |
| 1997 | 2 Million USD | -4.76% |
| 1996 | 2.1 Million USD | -61.11% |
| 1995 | 5.4 Million USD | 315.38% |
| 1994 | 1.3 Million USD | -51.85% |
| 1993 | 2.7 Million USD | -18.18% |
| 1992 | 3.3 Million USD | 3.13% |
| 1991 | 3.2 Million USD | 14.29% |
| 1990 | 2.8 Million USD | 100.0% |
| 1989 | 1.4 Million USD | 16.67% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2014 Q2 | 11.65 Million USD | 2.42% |
| 2014 Q1 | 11.38 Million USD | 3.05% |
| 2013 FY | 11.04 Million USD | -60.11% |
| 2013 Q2 | 27.42 Million USD | 0.99% |
| 2013 Q4 | 11.04 Million USD | -60.24% |
| 2013 Q3 | 27.77 Million USD | 1.31% |
| 2013 Q1 | 27.15 Million USD | -1.93% |
| 2012 Q2 | 31.36 Million USD | 0.75% |
| 2012 FY | 27.68 Million USD | -10.03% |
| 2012 Q1 | 31.13 Million USD | 1.16% |
| 2012 Q3 | 33.11 Million USD | 5.59% |
| 2012 Q4 | 27.68 Million USD | -16.4% |
| 2011 Q1 | 48.83 Million USD | 2.29% |
| 2011 Q4 | 30.77 Million USD | -31.05% |
| 2011 Q3 | 44.63 Million USD | 1.11% |
| 2011 FY | 30.77 Million USD | -35.55% |
| 2011 Q2 | 44.14 Million USD | -9.62% |
| 2010 Q1 | 50.09 Million USD | 3.72% |
| 2010 Q3 | 46.94 Million USD | -9.1% |
| 2010 Q4 | 47.74 Million USD | 1.71% |
| 2010 FY | 47.74 Million USD | -1.15% |
| 2010 Q2 | 51.63 Million USD | 3.08% |
| 2009 Q3 | 47.67 Million USD | 5.12% |
| 2009 Q2 | 45.35 Million USD | 4.6% |
| 2009 Q4 | 48.3 Million USD | 1.32% |
| 2009 Q1 | 43.35 Million USD | 6.11% |
| 2009 FY | 48.3 Million USD | 18.21% |
| 2008 FY | 40.85 Million USD | 45.73% |
| 2008 Q4 | 40.85 Million USD | 3.37% |
| 2008 Q3 | 39.52 Million USD | -0.02% |
| 2008 Q2 | 39.53 Million USD | 16.69% |
| 2008 Q1 | 33.87 Million USD | 20.83% |
| 2007 Q2 | 18.32 Million USD | -19.56% |
| 2007 FY | 28.03 Million USD | 48.03% |
| 2007 Q4 | 28.03 Million USD | 2.75% |
| 2007 Q3 | 27.28 Million USD | 48.92% |
| 2007 Q1 | 22.78 Million USD | 20.27% |
| 2006 FY | 18.94 Million USD | 621.78% |
| 2006 Q4 | 18.94 Million USD | 295.49% |
| 2006 Q2 | 2.26 Million USD | -6.19% |
| 2006 Q1 | 2.41 Million USD | -8.02% |
| 2006 Q3 | 4.78 Million USD | 111.52% |
| 2005 FY | 2.62 Million USD | 32.82% |
| 2005 Q1 | 1.75 Million USD | -11.31% |
| 2005 Q2 | 1.78 Million USD | 1.83% |
| 2005 Q3 | 2.54 Million USD | 42.85% |
| 2005 Q4 | 2.62 Million USD | 2.96% |
| 2004 Q4 | 1.97 Million USD | -67.95% |
| 2004 FY | 1.97 Million USD | -62.84% |
| 2004 Q1 | 6.09 Million USD | 14.55% |
| 2004 Q2 | 5.98 Million USD | -1.77% |
| 2004 Q3 | 6.16 Million USD | 3.05% |
| 2003 FY | 5.31 Million USD | -6.8% |
| 2003 Q2 | 5.23 Million USD | -4.01% |
| 2003 Q3 | 5.37 Million USD | 2.76% |
| 2003 Q4 | 5.31 Million USD | -1.16% |
| 2003 Q1 | 5.45 Million USD | -4.4% |
| 2002 Q1 | 2.47 Million USD | 36.98% |
| 2002 Q3 | 5.66 Million USD | 149.75% |
| 2002 FY | 5.7 Million USD | 216.32% |
| 2002 Q4 | 5.7 Million USD | 0.66% |
| 2002 Q2 | 2.26 Million USD | -8.15% |
| 2001 Q2 | 1.88 Million USD | -0.7% |
| 2001 Q1 | 1.9 Million USD | 14.51% |
| 2001 Q4 | 1.8 Million USD | -20.35% |
| 2001 FY | 1.8 Million USD | 8.57% |
| 2001 Q3 | 2.26 Million USD | 19.87% |
| 2000 Q3 | 1.97 Million USD | 33.0% |
| 2000 Q2 | 1.48 Million USD | -36.99% |
| 2000 Q1 | 2.35 Million USD | -63.18% |
| 2000 FY | 1.66 Million USD | -74.04% |
| 2000 Q4 | 1.66 Million USD | -15.88% |
| 1999 FY | 6.4 Million USD | 255.56% |
| 1999 Q4 | 6.4 Million USD | 6.67% |
| 1999 Q3 | 6 Million USD | 275.0% |
| 1999 Q2 | 1.6 Million USD | 0.0% |
| 1999 Q1 | 1.6 Million USD | -11.11% |
| 1998 FY | 1.8 Million USD | -10.0% |
| 1998 Q1 | 1.5 Million USD | -25.0% |
| 1998 Q3 | 1.5 Million USD | 7.14% |
| 1998 Q4 | 1.8 Million USD | 20.0% |
| 1998 Q2 | 1.4 Million USD | -6.67% |
| 1997 Q4 | 2 Million USD | 33.33% |
| 1997 FY | 2 Million USD | -4.76% |
| 1997 Q3 | 1.5 Million USD | 7.14% |
| 1997 Q2 | 1.4 Million USD | -17.65% |
| 1997 Q1 | 1.7 Million USD | -19.05% |
| 1996 Q4 | 2.1 Million USD | 31.25% |
| 1996 Q3 | 1.6 Million USD | -11.11% |
| 1996 Q2 | 1.8 Million USD | -41.94% |
| 1996 FY | 2.1 Million USD | -61.11% |
| 1996 Q1 | 3.1 Million USD | -42.59% |
| 1995 Q4 | 5.4 Million USD | 10.2% |
| 1995 FY | 5.4 Million USD | 315.38% |
| 1995 Q1 | 1.3 Million USD | 0.0% |
| 1995 Q2 | 4.4 Million USD | 238.46% |
| 1995 Q3 | 4.9 Million USD | 11.36% |
| 1994 FY | 1.3 Million USD | -51.85% |
| 1994 Q4 | 1.3 Million USD | -27.78% |
| 1994 Q3 | 1.8 Million USD | 0.0% |
| 1994 Q2 | 1.8 Million USD | -45.45% |
| 1994 Q1 | 3.3 Million USD | 22.22% |
| 1993 Q2 | 2.7 Million USD | -34.15% |
| 1993 FY | 2.7 Million USD | -18.18% |
| 1993 Q1 | 4.1 Million USD | 24.24% |
| 1993 Q3 | 3.1 Million USD | 14.81% |
| 1993 Q4 | 2.7 Million USD | -12.9% |
| 1992 Q1 | 3.9 Million USD | 21.88% |
| 1992 Q3 | 3.2 Million USD | 45.45% |
| 1992 Q4 | 3.3 Million USD | 3.13% |
| 1992 FY | 3.3 Million USD | 3.13% |
| 1992 Q2 | 2.2 Million USD | -43.59% |
| 1991 Q1 | 2.9 Million USD | 3.57% |
| 1991 Q4 | 3.2 Million USD | 18.52% |
| 1991 FY | 3.2 Million USD | 14.29% |
| 1991 Q3 | 2.7 Million USD | 0.0% |
| 1990 Q4 | 2.8 Million USD | 0.0% |
| 1990 FY | 2.8 Million USD | 100.0% |
| 1989 FY | 1.4 Million USD | 16.67% |
| 1989 Q4 | 1.4 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -40162.782% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -16.685% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 84.759% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1265.649% |
| Rebus Holdings, Inc. | 5.24 Million USD | -110.708% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 81.284% |
| Qrons Inc. | 1.48 Million USD | -641.935% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -800.764% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 85.257% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -24612.03% |
| Skye Bioscience, Inc. | 14.07 Million USD | 21.51% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 79.279% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -15.271% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2520.049% |
| SQZ Biotechnologies Company | 50.03 Million USD | 77.927% |
| Intellipharmaceutics International Inc. | 12 Million USD | 8.023% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -186.785% |
| Mesoblast Limited | 188.44 Million USD | 94.139% |
| Marizyme, Inc. | 26.67 Million USD | 58.594% |
| Genus plc | 485 Million USD | 97.723% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -89.047% |
| Pharming Group N.V. | 244.07 Million USD | 95.475% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -449.481% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -338.945% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -190.666% |
| ContraFect Corporation | 32.53 Million USD | 66.047% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -457.475% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -188.566% |
| IMV Inc. | 37.93 Million USD | 70.882% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 6.223% |
| MultiCell Technologies, Inc. | 1617.67 USD | -682690.0% |
| ONE Bio Corp. | 27.49 Million USD | 59.829% |
| Accustem Sciences Inc. | 1.07 Million USD | -923.433% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 85.733% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -422.219% |
| Q BioMed Inc. | 8.13 Million USD | -35.809% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 86.682% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -114.637% |
| Biomind Labs Inc. | 1.49 Million USD | -637.035% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 90.697% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -22.153% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 39.982% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -670.318% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -7673.172% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5391.999% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -92.232% |
| GB Sciences, Inc. | 5.41 Million USD | -103.88% |
| Alpha Cognition Inc. | 7.16 Million USD | -54.161% |
| HST Global, Inc. | 593.59 Thousand USD | -1760.751% |
| CSL Limited | 18.62 Billion USD | 99.941% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -777.172% |
| Halberd Corporation | 728.71 Thousand USD | -1415.713% |
| Enzolytics Inc. | 365.26 Million USD | 96.976% |
| Agentix Corp. | 2.51 Million USD | -339.954% |
| Resverlogix Corp. | 67.39 Million USD | 83.611% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1216.903% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.518% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -544.416% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 55.365% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 7.207% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -201.359% |
| AVAX Technologies, Inc. | 3.99 Million USD | -176.565% |
| Zenith Capital Corp. | 27.56 Thousand USD | -39964.163% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.167% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4528.16% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -195.779% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1522.317% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -307.329% |
| Kadimastem Ltd | 3.5 Million USD | -215.141% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -16402.994% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 78.025% |
| BioStem Technologies, Inc. | 15.9 Million USD | 30.553% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2276.87% |
| LadRx Corporation | 2.2 Million USD | -401.938% |
| Cell Source, Inc. | 15.8 Million USD | 30.123% |
| Regen BioPharma, Inc. | 5.45 Million USD | -102.383% |
| Regen BioPharma, Inc. | 5.45 Million USD | -102.383% |
| NovAccess Global Inc. | 7.86 Million USD | -40.512% |
| Affymax, Inc. | 8.87 Million USD | -24.51% |
| Itoco Inc. | 1.65 Million USD | -568.136% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -438.384% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -82.597% |
| Mobile Lads Corp. | 1.31 Million USD | -740.907% |
| CytoDyn Inc. | 127.89 Million USD | 91.364% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -26324.769% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -605.149% |
| SYBLEU INC | 681.41 Thousand USD | -1520.939% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -81.014% |
| International Stem Cell Corporation | 5.27 Million USD | -109.31% |
| Bioxytran, Inc. | 3.24 Million USD | -239.907% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1664.962% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -139.224% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 73.058% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 50.392% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -445.342% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -101.63% |
| Neutra Corp. | 973.52 Thousand USD | -1034.562% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 61.932% |
| PureTech Health plc | 125.58 Million USD | 91.205% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -193.982% |
| IXICO plc | 1.9 Million USD | -481.242% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 46.197% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 89.31% |
| CSL Limited | 18.62 Billion USD | 99.941% |
| Cellectis S.A. | 249.36 Million USD | 95.571% |